UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
18826,Deutsche Boerse,Twitter API,Twitter,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/HzsN8zH61r,nan,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/HzsN8zH61r,neutral,0.08,0.91,0.01,neutral,0.08,0.91,0.01,True,English,"['digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'HzsN8zH61r', 'digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'HzsN8zH61r']",2023-02-20,2023-02-27,Unknown
18897,Deutsche Boerse,Twitter API,Twitter,Trading Technologies facilitates access to Eurex EnLight - Deutsche BÃ¶rseâ€™s derivatives-focused exchange  Eurex anâ€¦ https://t.co/aF4i9R9wtz,nan,Trading Technologies facilitates access to Eurex EnLight - Deutsche BÃ¶rseâ€™s derivatives-focused exchange  Eurex anâ€¦ https://t.co/aF4i9R9wtz,neutral,0.04,0.96,0.01,neutral,0.04,0.96,0.01,True,English,"['Deutsche BÃ¶rse', 'Trading Technologies', 'derivatives-focused exchange', 'Eurex EnLight', 'access', 'Deutsche BÃ¶rse', 'Trading Technologies', 'derivatives-focused exchange', 'Eurex EnLight', 'access']",2023-02-21,2023-02-27,Unknown
18898,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse downgraded to Hold from Buy at Jefferies$DBOEY,nan,Deutsche Boerse downgraded to Hold from Buy at Jefferies$DBOEY,neutral,0.01,0.96,0.03,neutral,0.01,0.96,0.03,True,English,"['Deutsche Boerse', 'Buy', 'Jefferies', 'Deutsche Boerse', 'Buy', 'Jefferies']",2023-02-21,2023-02-27,Unknown
18899,Deutsche Boerse,Twitter API,Twitter,deutsche boerse plunge and everything else flat in the dax at the open was a little strange. escalated quickly :),nan,deutsche boerse plunge and everything else flat in the dax at the open was a little strange. escalated quickly :),negative,0.01,0.1,0.89,negative,0.01,0.1,0.89,True,English,"['deutsche boerse plunge', 'everything', 'dax', 'open', 'deutsche boerse plunge', 'everything', 'dax', 'open']",2023-02-21,2023-02-27,Unknown
18900,Deutsche Boerse,Twitter API,Twitter,what happened to deutsche boerse here? glitch? gm dax https://t.co/QCsbVd15Wu,nan,what happened to deutsche boerse here? glitch? gm dax https://t.co/QCsbVd15Wu,negative,0.01,0.05,0.93,negative,0.01,0.05,0.93,True,English,"['deutsche boerse', 'glitch', 'gm', 'QCsbVd15Wu', 'deutsche boerse', 'glitch', 'gm', 'QCsbVd15Wu']",2023-02-21,2023-02-27,Unknown
18965,Euroclear,Twitter API,Twitter,Wells Fargo plans financial planning upgrade to its mobile app #AAA Websites Euroclear Fintech https://t.co/0V0WVFHwzm #regtech,nan,Wells Fargo plans financial planning upgrade to its mobile app #AAA Websites Euroclear Fintech https://t.co/0V0WVFHwzm #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['financial planning upgrade', 'Wells Fargo', 'mobile app', 'Fintech', 'financial planning upgrade', 'Wells Fargo', 'mobile app', 'Fintech']",2023-02-22,2023-02-27,Unknown
18966,Euroclear,Twitter API,Twitter,@Mousacisse1 How is that possible? When they pay donâ€™t they have to pay via euroclear and euroclear is holding theâ€¦ https://t.co/U7QYM47S3C,nan,@Mousacisse1 How is that possible? When they pay donâ€™t they have to pay via euroclear and euroclear is holding theâ€¦ https://t.co/U7QYM47S3C,neutral,0.05,0.92,0.03,neutral,0.05,0.92,0.03,True,English,"['Mousacisse1', 'euroclear', 'U7QYM47S3C', 'Mousacisse1', 'euroclear', 'U7QYM47S3C']",2023-02-22,2023-02-27,Unknown
18967,Euroclear,Twitter API,Twitter,National Australia Bank builds its own fintechs #AAA Websites Euroclear Fintech https://t.co/BV1abMYlfa #regtech,nan,National Australia Bank builds its own fintechs #AAA Websites Euroclear Fintech https://t.co/BV1abMYlfa #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['National Australia Bank', 'fintechs', 'BV1abMYlfa', 'regtech', 'National Australia Bank', 'fintechs', 'BV1abMYlfa', 'regtech']",2023-02-22,2023-02-27,Unknown
18971,Deutsche Boerse,Twitter API,Twitter,@ToffCap1 Maybe Deutsche Boerse steps in? Aligns nicely for them given they already have a fund biz.,nan,@ToffCap1 Maybe Deutsche Boerse steps in? Aligns nicely for them given they already have a fund biz.,positive,0.99,0.01,0.0,positive,0.99,0.01,0.0,True,English,"['Deutsche Boerse', 'fund biz', 'Aligns', 'Deutsche Boerse', 'fund biz', 'Aligns']",2023-02-22,2023-02-27,Unknown
18972,Deutsche Boerse,Twitter API,Twitter,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/hS88ypbawd,nan,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/hS88ypbawd,positive,0.68,0.31,0.01,positive,0.68,0.31,0.01,True,English,"['Deutsche BÃ¶rse', 'partnership', 'Deutsche BÃ¶rse', 'partnership']",2023-02-22,2023-02-27,Unknown
18973,Deutsche Boerse,Twitter API,Twitter,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/CxboBmGTGW,nan,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/CxboBmGTGW,neutral,0.08,0.91,0.02,neutral,0.08,0.91,0.02,True,English,"['new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone']",2023-02-22,2023-02-27,Unknown
19029,Deutsche Boerse,Twitter API,Twitter,The participating #exchange groups include Deutsche Boerse Group  Euronext  Nasdaq  and SIX Group  as well as the lâ€¦ https://t.co/aLjS1odRh8,nan,The participating #exchange groups include Deutsche Boerse Group  Euronext  Nasdaq  and SIX Group  as well as the lâ€¦ https://t.co/aLjS1odRh8,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['participating #exchange groups', 'Deutsche Boerse Group', 'SIX Group', 'Euronext', 'Nasdaq', 'participating #exchange groups', 'Deutsche Boerse Group', 'SIX Group', 'Euronext', 'Nasdaq']",2023-02-23,2023-02-27,Unknown
19030,Deutsche Boerse,Twitter API,Twitter,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/grBSB3xX4z,nan,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/grBSB3xX4z,positive,0.9,0.1,0.0,positive,0.9,0.1,0.0,True,English,"['Deutsche BÃ¶rse', 'partnership', 'grBSB3xX4z', 'Deutsche BÃ¶rse', 'partnership', 'grBSB3xX4z']",2023-02-23,2023-02-27,Unknown
19121,Deutsche Boerse,Twitter API,Twitter,I found you a Death Cross on the daily chart of Deutsche Boerse AG. $0H3T #0H3T #deathcross #bearishâ€¦ https://t.co/iT6QYU7tWe,nan,I found you a Death Cross on the daily chart of Deutsche Boerse AG. $0H3T #0H3T #deathcross #bearishâ€¦ https://t.co/iT6QYU7tWe,negative,0.0,0.48,0.52,negative,0.0,0.48,0.52,True,English,"['Deutsche Boerse AG', 'Death Cross', 'daily chart', 'Deutsche Boerse AG', 'Death Cross', 'daily chart']",2023-02-24,2023-02-27,Unknown
19217,Euroclear,Twitter API,Twitter,Visa aims to get business owners to upgrade from consumer cards #AAA Websites Euroclear Fintech https://t.co/1Yd6NGMBu6 #regtech,nan,Visa aims to get business owners to upgrade from consumer cards #AAA Websites Euroclear Fintech https://t.co/1Yd6NGMBu6 #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['business owners', 'consumer cards', 'Visa', 'Fintech', 'business owners', 'consumer cards', 'Visa', 'Fintech']",2023-02-24,2023-02-27,Unknown
19218,Euroclear,Twitter API,Twitter,MidWest America Federal Credit Union in Indiana names new CEO #AAA Websites Euroclear Fintech https://t.co/VgUCkfzA2V #regtech,nan,MidWest America Federal Credit Union in Indiana names new CEO #AAA Websites Euroclear Fintech https://t.co/VgUCkfzA2V #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['MidWest America Federal Credit Union', 'Indiana names', 'new CEO', 'Fintech', 'VgUCkfzA2V', 'MidWest America Federal Credit Union', 'Indiana names', 'new CEO', 'Fintech', 'VgUCkfzA2V']",2023-02-24,2023-02-27,Unknown
19221,Deutsche Boerse,Twitter API,Twitter,@DeutscheBoerse has partnered with @googlecloud to boost its outsourcing capabilities and better serve clients. Leâ€¦ https://t.co/TlaOFVL0vW,nan,@DeutscheBoerse has partnered with @googlecloud to boost its outsourcing capabilities and better serve clients. Leâ€¦ https://t.co/TlaOFVL0vW,positive,0.69,0.31,0.0,positive,0.69,0.31,0.0,True,English,"['outsourcing capabilities', 'clients', 'TlaOFVL0vW', 'outsourcing capabilities', 'clients', 'TlaOFVL0vW']",2023-02-25,2023-02-27,Unknown
19276,Deutsche Boerse,Twitter API,Twitter,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda andâ€¦ https://t.co/rHyKuSyQiD,nan,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda andâ€¦ https://t.co/rHyKuSyQiD,neutral,0.13,0.87,0.01,neutral,0.13,0.87,0.01,True,English,"['kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda', 'rHyKuSyQiD', 'kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda', 'rHyKuSyQiD']",2023-02-26,2023-02-27,Unknown
19281,Euroclear,Bing API,https://www.privataaffarer.se/ctek-ab-ctek-announces-the-terms-of-its-rights-issue-1677528000,CTEK AB: CTEK announces the terms of its rights issue,Those who are registered as shareholders in CTEK's share register maintained by Euroclear Sweden on the record date on 8 March 2023 will receive one (1) subscription right for each CTEK share held. Five (5) subscription rights entitle to subscription for two (2) new shares in CTEK.,"On 8 February 2023  CTEK AB (publ) (""CTEK"" or the ""Company"") announced that the board of directors (the ""Board"") of CTEK  subject to approval from the extraordinary general meeting to be held on 3 March 2023  has resolved on a rights issue of approximately SEK 350 million (the ""Rights Issue""). Today  the Board announces the terms of the Rights Issue. The net proceeds from the Rights Issue are intended to be used to repay part of the Company's loans in order to decrease indebtedness and to ensure investments in product development and the Company's supply chain.SummaryThose who are registered as shareholders in CTEK's share register maintained by Euroclear Sweden on the record date on 8 March 2023 will receive one (1) subscription right for each CTEK share held. Five (5) subscription rights entitle to subscription for two (2) new shares in CTEK.The last day of trading in CTEK shares inclusive of the right to participate in the Rights Issue is 6 March 2023.The subscription price has been set at SEK 17.50 per share. Provided that the Rights Issue is fully subscribed  CTEK will consequently raise approximately SEK 350 million before transaction costs.The subscription period will run from and including 10 March 2023 up to and including 24 March 2023.The Company's largest shareholder  Investment AB Latour (publ) (""Latour"")  has undertaken to vote in favour of the Rights Issue at the extraordinary general meeting and to subscribe for its pro rata share of 30.57 percent of the outstanding shares and votes in CTEK in the Rights Issue. In addition  Skirner AB (""Skirner"") and AMF TjÃ¤nstepension AB (""AMF"")  together holding shares representing 10.45 percent of the outstanding shares and votes in the Company  have undertaken to vote in favour of the Rights Issue at the extraordinary general meeting and to subscribe for their respective pro rata share in the Rights Issue. In addition to the subscription undertaking Latour has entered into a guarantee agreement for the remaining part of the Rights Issue which is not covered by the subscription undertakings mentioned above. Thus  the Rights Issue is fully covered by subscription undertakings and guarantee agreements from current shareholders.FjÃ¤rde AP Fonden (""AP4"")  Swedbank Robur Fonder AB (""Swedbank Robur"") and SEB Fonder (""SEB"")  together holding shares representing 17.37 percent of the outstanding shares and votes in the Company  have expressed their support for the Rights Issue.The Board has convened an extraordinary general meeting to be held on 3 March 2023.The net proceeds from the Rights Issue are intended to be used to repay part of the Company's loans in order to decrease indebtedness and to ensure investments in product development and the Company's supply chain.The Rights IssueThose who are registered as shareholders in CTEK's share register maintained by Euroclear Sweden on the record date 8 March 2023 will receive one (1) subscription right for each share held in CTEK. Five (5) subscription rights entitle to subscription for two (2) new shares in CTEK. To the extent that new shares are not subscribed for by exercise of subscription rights  they shall be allotted to shareholders and other investors who have subscribed for shares without exercise of subscription rights. As confirmation of the allotment of new shares subscribed for without exercise of subscription rights  a transfer note will be sent to subscribers on or around 28 March 2023. No notice will be sent to subscribers who have not received an allotment.The Rights Issue  if fully subscribed  will increase CTEK's share capital by a maximum of SEK 19 993 221 from SEK 49 983 054 to no more than SEK 69 976 275 through the issuance of no more than 19 993 221 new shares. After the Rights Issue  the number of shares in CTEK will amount to no more than 69 976 275 shares.The subscription price has been set at SEK 17.50 per share. Provided that the Rights Issue is fully subscribed  CTEK will consequently raise approximately SEK 350 million before transaction costs.The record date for participation in the Rights Issue is on 8 March 2023. This means that the share will be traded inclusive of the right to receive subscription rights up to and including 6 March 2023. The subscription period will run from and including 10 March 2023 up to and including 24 March 2023. Trading in subscription rights will take place on Nasdaq Stockholm during the period from and including 10 March 2023 up to and including 21 March 2023.Shareholders who choose not to participate in the Rights Issue will have their holding diluted by a total of 19 993 221 new shares  corresponding to approximately 28.6 percent of the total number of shares in CTEK after the Rights Issue. These shareholders will have the possibility to compensate themselves financially for the dilution effect by selling their subscription rights.Subscription undertakings  guarantee agreements and shareholder supportThe Company's largest shareholder  Latour  has undertaken to vote in favour of the Rights Issue at the extraordinary general meeting and to subscribe for its pro rata share of 30.57 percent of the outstanding shares and votes in CTEK in the Rights Issue. In addition  Skirner and AMF  together holding shares representing 10.45 percent of the outstanding shares and votes in the Company  have undertaken to vote in favour of the Rights Issue at the extraordinary general meeting and to subscribe for their respective pro rata share in the Rights Issue. In addition to the subscription undertaking  Latour has entered into a guarantee agreement for the remaining part of the Rights Issue which is not covered by the subscription undertakings mentioned above. Thus  the Rights Issue is fully covered by subscription undertakings and guarantee agreements from current shareholders. AP4  Swedbank Robur and SEB  together holding shares representing 17.37 percent of the outstanding shares and votes in the Company  have expressed their support for the Rights Issue.Extraordinary general meetingThe Rights issue is subject to approval by an extraordinary general meeting to be held on 3 March 2023. Notice for the extraordinary general meeting is available on CTEK's website  www.ctek.com.Prospectus and indicative timetable for the Rights IssueThe prospectus is expected to be published around 8 March 2023 and will contain complete information about the Rights Issue.3 March 2023 Extraordinary general meeting to approve the Rights Issue6 March 2023 Last day of trading in shares inclusive of the right toparticipate in the Rights Issue8 March 2023 Record date for participation in the Rights Issue withpreferential rights8 March 2023 Publication of the prospectus10 March 2023 Trading in subscription rights- 21 March202310 March 2023 Subscription period- 24 March202310 March 2023 Trading in paid subscribed shares (BTA)- 28 March202328 March 2023 Announcement of the outcome of the Rights IssueAround 28 Transfer note regarding allotment of shares subscribed forMarch 2023 without subscription rights distributedLock-up commitmentsIn connection with the Rights Issue  the Company has  subject to customary exceptions  agreed to a lock-up undertaking on future share issuances for a period of 180 calendar days following the completion of the Rights Issue. Members of the Company's Board and management have  subject to customary exceptions  agreed not to sell their shares in the Company for a period of 90 calendar days following the completion of the Rights Issue.AdvisorsIn relation to the Rights Issue  the Company has engaged Carnegie Investment Bank AB (publ) and Swedbank AB (publ) as Joint Global Coordinators and Joint Bookrunners. Advokatfirman Vinge KB is legal advisor in relation to the Rights Issue.This information constitutes inside information as CTEK AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact persons below for publication 27 February 2023 at 20:00 CET.The Board of CTEK AB (publ)",neutral,0.0,1.0,0.0,neutral,0.02,0.97,0.01,True,English,"['rights issue', 'CTEK AB', 'terms', 'FjÃ¤rde AP Fonden', 'AMF TjÃ¤nstepension AB', 'respective pro rata share', 'Swedbank Robur Fonder AB', 'extraordinary general meeting', 'Investment AB Latour', 'Five (5) subscription rights', 'one (1) subscription right', 'two (2) new shares', 'The Rights Issue', 'Skirner AB', 'SEB Fonder', 'CTEK AB', 'subscription price', 'subscription undertaking', '19,993,221 new shares', 'net proceeds', 'product development', 'supply chain', 'Euroclear Sweden', 'record date', 'last day', 'transaction costs', 'largest shareholder', 'other investors', 'transfer note', 'Nasdaq Stockholm', 'dilution effect', 'share register', 'share capital', 'subscription period', 'outstanding shares', 'guarantee agreement', 'The Board', 'The Company', 'shareholder support', 'remaining part', 'current shareholders', 'CTEK share', 'total number', '69,976,275 shares', 'agreements', '8 February', 'directors', 'approval', '3 March', 'SEK', 'terms', 'loans', 'order', 'indebtedness', 'investments', 'Summary', '8 March', 'trading', '6 March', '10 March', '24 March', 'favour', '30.57 percent', 'votes', 'addition', '10.45 percent', 'AP4', '17.37 percent', 'extent', 'exercise', 'confirmation', 'allotment', 'subscribers', 'notice', 'maximum', 'issuance', 'participation', 'place', '21 March', 'holding', '28.6 percent', 'possibility']",2023-02-27,2023-02-27,privataaffarer.se
19282,Euroclear,Twitter API,Twitter,@NOELreports It seems that this is mainly due to the presence of Euroclear's head office in Belgium.,nan,@NOELreports It seems that this is mainly due to the presence of Euroclear's head office in Belgium.,neutral,0.0,0.99,0.01,neutral,0.0,0.99,0.01,True,English,"['head office', 'NOELreports', 'presence', 'Euroclear', 'Belgium', 'head office', 'NOELreports', 'presence', 'Euroclear', 'Belgium']",2023-02-27,2023-02-27,Unknown
19283,Euroclear,Twitter API,Twitter,Belgium:SWIFT and Euroclear HQ: Brussels.Antwerp is World's #1 largest International Diamond Exchange.ðŸ‘‡ https://t.co/r8PEItDRW7,nan,Belgium:SWIFT and Euroclear HQ: Brussels.Antwerp is World's #1 largest International Diamond Exchange.ðŸ‘‡ https://t.co/r8PEItDRW7,neutral,0.02,0.97,0.01,neutral,0.02,0.97,0.01,True,English,"['Euroclear HQ', 'Belgium', 'SWIFT', 'Brussels', 'Antwerp', 'World', 'Euroclear HQ', 'Belgium', 'SWIFT', 'Brussels', 'Antwerp', 'World']",2023-02-27,2023-02-27,Unknown
19284,Euroclear,Twitter API,Twitter,@ryba__pila @NOELreports Itâ€™s because swift and euroclear are based in Belgium,nan,@ryba__pila @NOELreports Itâ€™s because swift and euroclear are based in Belgium,neutral,0.03,0.96,0.01,neutral,0.03,0.96,0.01,True,English,"['NOELreports', 'Belgium', 'NOELreports', 'Belgium']",2023-02-27,2023-02-27,Unknown
19285,Euroclear,Twitter API,Twitter,@NOELreports Swift and euroclear are both based in Belgium,nan,@NOELreports Swift and euroclear are both based in Belgium,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['euroclear', 'Belgium', 'euroclear', 'Belgium']",2023-02-27,2023-02-27,Unknown
19286,Deutsche Boerse,Bing API,https://www.digitalcameraworld.com/news/shortlisted-photographers-for-dollar35000-deutsche-borse-prize-announced,Shortlisted photographers for $35 000 Deutsche BÃ¶rse prize announced,The winner of the Deutsche BÃ¶rse Photography Foundation exhibition will be  announced at an awards ceremony held at The Photographers' Gallery in London on 11 May 2023. A grand prize of Â£30 000 (around $36 ,"The Deutsche BoÌˆrse Photography Foundation Prize has just announced the four shortlisted photographers that will appear in the 2023 exhibition. Taking place at The Photographerâ€™s Gallery in London from March 3 - June 11  the prize celebrates photographers who redefine genres  push the boundaries and explore themes of race  identity  gender and traditions.This yearâ€™s shortlist includes Belgian photographer Bieke Depoorter for her exhibition A Chance Encounter at CO Berlin. Blurring the lines between photographer and subject  Depoorterâ€™s nominated project explores two chance encounters through the series Michael  and Agata. While Michael examines the disappearance of a man she met on a street in Portland  Agata explores a first meeting in a Parisian strip-club evolving with the constantly changing narrative.Malcolm X (Image credit: Samuel Fosso)Cameroonian/Nigerian photographer Samuel Fosso was also selected for his self-named series which was exhibited at the Maison EuropÃ©enne de la Photographie in Paris from November 2021 to March 2022. Through a series of self-portraits that Fosso first started taking in the 1970s  he takes on the role of key historical figures and social archetypes as a way of exploring African identity and how African people exist in the world.Artist and filmmaker Arthur Jafa was recognized for his largest exhibition to date  Live Evil at Luma Arles  France. Using clever juxtaposition and lyrical editing Jafa creates thought-provoking pieces containing resonant cultural artifacts. He examines the black experience through an eschewing linear narrative which allows the viewer to consider `'the power  beauty and alienation of Black music"" in Jafa's own words.A photo from the series  Michael (Image credit: Bieke Depoorter)The final photographer to be shorted is Frida Orubano for her series of sculptural collages and digital works. I have seen a million pictures of my face and still I have no idea exhibited at Fotomusei  Winterthur and explorea questions of race  sexuality and identity through striking black and white  abstract imagery.Orupabo's work is complex  multi-dimensional and delivers a poetic maneuver that criticizes single-view depictions of Black lives. Orupabo hopes to spark interest in how photography has contributed to the formation and reputation of colonial relations and violence and how the story of Black people is almost entirely absent.Batwoman (Image credit: Frida Orupabo)The winner of the Deutsche BÃ¶rse Photography Foundation exhibition will be  announced at an awards ceremony held at The Photographers' Gallery (opens in new tab)in London on 11 May 2023. A grand prize of Â£30 000 (around $36 000) is up for grabs for the overall winner and each finalist will also receive Â£5 000 ($6 000).The exhibition will run from the 3rd of May until Sunday 11 June at London's Photographers Gallery  before heading to the Muzeum Fotigrafii w Krakowie in Krakow  Poland from June 30 - September 17  2023.Photographer reframing the black experience wins Deutsche BÃ¶rse Prize",neutral,0.02,0.98,0.0,negative,0.0,0.01,0.99,True,English,"['$35,000 Deutsche BÃ¶rse prize', 'Shortlisted photographers', 'The Deutsche BoÌˆrse Photography Foundation Prize', 'Maison EuropÃ©enne de la Photographie', 'Deutsche BÃ¶rse Photography Foundation exhibition', 'Deutsche BÃ¶rse Prize', 'Belgian photographer Bieke Depoorter', 'Cameroonian/Nigerian photographer Samuel Fosso', 'A Chance Encounter', 'two chance encounters', 'key historical figures', 'resonant cultural artifacts', 'white, abstract imagery', 'eschewing linear narrative', 'four shortlisted photographers', ""The Photographers' Gallery"", 'grand prize', 'changing narrative', 'final photographer', 'Photographers Gallery', 'largest exhibition', 'CO Berlin', 'first meeting', 'Parisian strip-club', 'Malcolm X', 'Image credit', 'social archetypes', 'African people', 'Luma Arles', 'clever juxtaposition', 'lyrical editing', 'thought-provoking pieces', 'black experience', 'Black music', 'Frida Orubano', 'sculptural collages', 'digital works', 'million pictures', 'striking black', 'poetic maneuver', 'single-view depictions', 'Black lives', 'colonial relations', 'Black people', 'awards ceremony', 'new tab', 'Muzeum Fotigrafii', 'overall winner', 'African identity', 'Arthur Jafa', 'Frida Orupabo', 'Sunday 11 June', '2023 exhibition', 'place', 'London', 'March', 'genres', 'boundaries', 'themes', 'race', 'gender', 'traditions', 'lines', 'subject', 'project', 'series', 'Michael', 'Agata', 'disappearance', 'street', 'Portland', 'named', 'November', 'self-portraits', '1970s', 'role', 'way', 'world', 'Artist', 'filmmaker', 'date', 'Evil', 'France', 'viewer', 'power', 'beauty', 'alienation', 'words', 'face', 'idea', 'Fotomusei', 'Winterthur', 'questions', 'sexuality', 'interest', 'formation', 'reputation', 'violence', 'story', 'Batwoman', '11 May', 'grabs', 'finalist', '3rd', 'Krakowie', 'Poland', 'September']",2023-02-27,2023-02-27,digitalcameraworld.com
19287,Deutsche Boerse,Twitter API,Twitter,Epic change on DAX40: Germany's Commerzbank will rejoin #DAX index on Feb. 27  Deutsche Boerse announced late on Frâ€¦ https://t.co/zUBAL6widy,nan,Epic change on DAX40: Germany's Commerzbank will rejoin #DAX index on Feb. 27  Deutsche Boerse announced late on Frâ€¦ https://t.co/zUBAL6widy,neutral,0.08,0.91,0.01,neutral,0.08,0.91,0.01,True,English,"['Epic change', 'Deutsche Boerse', 'DAX40', 'Germany', 'Commerzbank', 'Feb.', 'Epic change', 'Deutsche Boerse', 'DAX40', 'Germany', 'Commerzbank', 'Feb.']",2023-02-27,2023-02-27,Unknown
19288,EuroNext,NewsApi.org,https://seekingalpha.com/article/4581872-valeo-the-2025-targets-look-juicy-but-markets-are-still-challenging,Valeo: 2025 Targets Look Juicy But Markets Still Challenging (OTCMKTS:VLEEF),Valeo's net income and free cash flow results were okay in 2022 but certainly not impressive. Click here to read more about the long-term prospects of Valeo.,"DarthArt/iStock Editorial via Getty ImagesIntroductionCar parts suppliers are tough to invest in. I thought Faurecia (now Forvia) was cheap when I invested  but the stock continued to go down before finally catching a bid at the end of last year. Valeo (OTCPK:VLEEF) (OTCPK:VLEEY)  another French company active in the car parts supply chain  optically looks cheap  but there are no real catalysts to push the share price higher. As Valeo dropped by almost 10% on its earnings report (and was trading at a loss of in excess of 10% during the trading day)  I wanted to have a quick look under the hood to see if the market is overreacting or if a short-term hiccup is creating a long-term opportunity. Valeo focuses on the powertrain systems  comfort and driving assistance systems (with for instance the LiDAR systems detecting crossing pedestrians or cyclists) and the thermal and visibility systems.Valeo Investor RelationsValeoâ€™s primary listing in France has FR as ticker symbol. The volume on Euronext Paris is substantially higher (almost 1 million shares) than anywhere else so I would strongly recommend to trade in Valeoâ€™s shares using its Paris listing. There also are options available.Yahoo FinanceA healthy amount of free cash flow was generated in 2022 - thanks to a working capital release2022 wasnâ€™t a bad year for Valeo. The total revenue increased to in excess of 20B EUR but the company clearly experienced pressure on its margins as the operating margin decreased from 4% to just 3.2%.Valeo Investor RelationsThat being said  the contribution from equity-accounted companies improved dramatically: whereas Valeo had to confess a 243M EUR loss in 2021  this was converted into a 115M EUR contribution in 2022 which helped to boost the operating income including the contribution from these equity-accounted companies by almost 2/3rds. The net income came in at 295M EUR of which 230M EUR was attributable to the shareholders of Valeo and 65M EUR was attributable to non-controlling interests. This means the EPS was 0.95 EUR  an increase from the 0.73 EUR in FY 2021 despite the operating margin pressure and the higher finance expenses (131M EUR versus just 60M EUR).Valeo Investor RelationsAs Valeo has a relatively high net debt level (see later)  I'm more interested in seeing if the company is actually generating a positive free cash flow  which will help to keep the debt levels under control.The company reported an operating cash flow of 1.91B EUR in FY 2022 but this includes a nice contribution of 231M EUR from working capital changes which would have to be deduct again. I also see the company paid 291M in cash taxes but only owed 214M EUR based on the income statement. We should also deduct the 59M EUR in dividends paid to non-controlling interests and the net interest payments of 100M EUR.Valeo Investor RelationsThis means the adjusted operating cash flow in FY 2022 was approximately 1.6B EUR.We also see the total capex was 1.5B EUR  resulting in an underlying free cash flow of just 100M EUR. Thatâ€™s hardly worth talking about but letâ€™s not forget Valeo is in an ""investment modus"" as it has ambitious growth plans for 2025. Valeo expects to reach a total revenue of 24B EUR in 2025  and this should be combined with higher margins.Valeo Investor RelationsIt wants to achieve a 14.5% EBITDA margin (which basically means Valeo is implying the 2025 EBITDA result will reach 3.5B EUR). But even more important is the guidance for a 6.5% EBIT margin.Valeo Investor RelationsBased on a revenue of 24B EUR  Valeoâ€™s 2025 guidance implies an EBIT result of approximately 1.55B EUR. But while Valeo was guiding for an 800M-1B EUR free cash flow result  Iâ€™m a bit more cautious. The 2022-2025 projections were published in Q1 2022  before interest rates started to increase pretty dramatically.And with in excess of 6B EUR in gross debt (see below)  increasing interest rates will become an important factor. Earlier this year  a 500M EUR bond with a 0.625% coupon matured and later this year another (much smaller) debt issue of 115M EUR with a 0.95% coupon has to be refinanced as well.Valeo Investor RelationsIf I would assume an average interest rate of 4.25% on the 6B EUR in gross debt  the interest expenses will increase to almost 260M EUR. Deducting this from the 1.55B EUR EBIT guidance would result in a pre-tax income of 1.3B EUR and a net income of approximately 950M EUR of which I estimate about 100-125M EUR would be attributable to non-controlling interests. The net income attributable to the Valeo shareholders would then be around 825-850M EUR. This represents an EPS of approximately 3.5 EUR per share.Investment thesisIâ€™m only lukewarm when I see Valeoâ€™s financial results for 2022 and although the guidance for 2023 looks encouraging with an anticipated 10% revenue increase and slight EBITDA margin increase I remain on the sidelines here until I see Valeo has indeed turned a corner.The 2025 targets are very enticing so I will keep an eye on Valeo as it works toward those targets but it's clear this now is an execution story. And Valeo will for sure have to keep an eye on its debt level and interest expenses while advancing its strategic plan.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.",neutral,0.02,0.92,0.05,mixed,0.53,0.07,0.4,True,English,"['Valeo', '2025 Targets', 'Markets', '800M-1B EUR free cash flow result', 'positive free cash flow', 'underlying free cash flow', 'car parts supply chain', 'high net debt level', 'slight EBITDA margin increase', 'operating cash flow', 'Car parts suppliers', 'Valeo Investor Relations Valeo', '1.55B EUR EBIT guidance', 'working capital release', 'working capital changes', 'ambitious growth plans', '500M EUR bond', 'smaller) debt issue', 'average interest rate', 'driving assistance systems', 'net interest payments', 'increasing interest rates', '243M EUR loss', 'higher finance expenses', 'operating margin pressure', '115M EUR contribution', '2025 EBITDA result', 'EBIT result', 'cash taxes', '14.5% EBITDA margin', '6.5% EBIT margin', 'interest expenses', '230M EUR', '59M EUR', 'operating income', 'net income', 'debt levels', 'gross debt', 'Yahoo Finance', 'powertrain systems', 'LiDAR systems', 'visibility systems', '6B EUR', '10% revenue increase', 'iStock Editorial', 'Getty Images', 'last year', 'real catalysts', 'earnings report', 'trading day', 'quick look', 'short-term hiccup', 'long-term opportunity', 'primary listing', 'ticker symbol', 'Euronext Paris', 'Paris listing', 'healthy amount', 'bad year', 'equity-accounted companies', 'non-controlling interests', 'income statement', 'total capex', 'investment modus', 'higher margins', '2022-2025 projections', 'important factor', 'pre-tax income', 'Investment thesis', 'financial results', 'total revenue', 'nice contribution', 'share price', '1 million shares', 'Valeo shareholders', 'French company', '3.5 EUR', '2025 guidance', 'DarthArt', 'Introduction', 'Faurecia', 'Forvia', 'bid', 'end', 'VLEEF', 'VLEEY', 'excess', 'market', 'comfort', 'instance', 'crossing', 'pedestrians', 'cyclists', 'thermal', 'France', 'volume', 'options', '20B', '2/3rds', '295M', 'EPS', 'FY', '60M', '1.91B', '231M', '214M', '100M', '3.5B', '24B', 'Q1', '0.625% coupon', '0.95% coupon', '950M', '100-125M', 'sidelines', 'corner', '2025 targets', 'eye', '0.73', '2023']",2023-02-26,2023-02-27,seekingalpha.com
19289,EuroNext,NewsApi.org,https://seekingalpha.com/article/4582181-6-european-reits-to-consider,6 European REITs To Consider,In this article  I've highlighted six under-the-radar European REITs. Check out the comparison of the REITs and the ones I like the most.,Andrii YalanskyiIntroductionIn this article I will start with short company highlights of under the radar European REITs and compare them at the end. Some are focused on only one type of real estate  while others have exposure to several sectors. In terms of size  they range from 1.3 to 17.4 billion EUR in assets.CovivioCovivio (OTCPK:GSEFF) runs a highly diversified business model. The company has 55% of its assets in offices  30% in residential real estate and 15% in hotels:Covivio Q4 2022 Results PresentationThe average debt maturity is 6.3 years with a 1.24% cost of debt. Cost of debt expected to increase to only 2.5% in 2026 thanks to hedging. Occupancy is 94.4% for offices  99.2% for residential and 100% for hotels.Overall  the current strategy is to focus on debt reduction via share dividend  as well as divestments. Some offices are to be converted to residential use.NSINSI (NSI on Euronext) is focused only on office real estate in the Netherlands:NSI Q4 2022 Results PresentationThe average debt maturity is 4.7 years with a cost of debt of 2%. The occupancy of 93.8% is slightly worse than Covivio's office portfolio (-0.6%). The main headwind facing the company are changes to the Dutch REIT legislation expected to take effect into 2025  which may negatively impact earnings.MercialysMercialys (OTCPK:MEIYF) is focused on retail assets in France but strives to diversify tenants via mixed use such as co-working spaces where possible.Mercialys Q4 2022 Results PresentationThe average debt maturity is 4.9 years and cost of debt is 2%. When accessing growth opportunities  the company will focus on mixed use properties with good development margins (at minimum 2.5% above financing cost).WereldhaveWereldhave (OTCPK:WRDEF) is focused on retail assets in the Netherlands  France and Belgium  where it operates some offices as well:Wereldhave Q4 2022 Results PresentationJust as Mercialys  the company is striving to increase the mixed use element in its retail portfolio. The average debt maturity is 3.5 years with an average cost of debt of 2.5%. The main differentiator for the company are residential development projects to be delivered in 2023-2025+. Just as NSI  it will likely take a hit from changes to Dutch REIT regime to take effect in 2025  which it estimates at 5% of net income.VastnedVastned (VASTN on Euronext) is focused on retail properties in several countries  primarily the Netherlands  France and Belgium:Vastned Q4 2022 Results PresentationThe average cost of debt is 1.91% with an average maturity of just 2.2 years. The company is somewhat unique in not issuing a direct result (FFO) guidance for 2023 due to rising interest rates and economic uncertainty.CofinimmoCofinimmo (OTC:CFMOF) is active in three sectors - healthcare (70%)  offices (22%) and distribution networks (8%) in 9 countries  with a total portfolio of 6.2 billion EUR:Cofinimmo Q4 2022 Results PresentationThe average cost of debt is 1.2% with an average debt maturity of 5 years. The company has a relatively elevated debt to assets ratio of 45.6% compared to the other REITs in the overview. Thus it offers the option to receive the dividend in shares in order to reduce leverage. A key differentiator is the long average residual lease length of 13 years thanks to its focus on healthcare.Comparison TableFor all companies in the below comparison I will use the market price in EUR. I will also implement this approach to estimate the market-implied net initial yield:Market-implied net initial yield = Valuation net initial yield / Division factor where:Division factor = Price/NDV Ratio * (1 - Loan-to-value ratio) + Loan-to-value ratioNDV stands for Net Disposal Value  a common metric reported by European REITs as a proxy for Net asset value.Also where available  I will adjust the NDV to account for the market value of fixed interest debt (for some REITs the NDV is artificially inflated due to low prices of bonds they have issued). Where possible  I will generally use the EPRA net initial yield for valuation net initial yield.Here is the calculation for Covivio as an example:1. EPRA NDV = 97.4 EUR/share (107.8 EUR/share reported minus 10.4 EUR/share mark-to-market of fixed rate debt)2. Loan-to-value = 39.5%3. Valuation net initial yield = 3.6%4. Price at the time of writing = 60 EURYou get a P/NDV Ratio of 60 / 97.4 = 0.616  a division factor of 0.77 (0.616 * (1-0.395) + 0.395). The EPRA NIY is 3.6% which divided by out unrounded division factor of 0.7678 gives us a market-implied net initial yield of roughly 4.69%:Company\Metric LTV Valuation NIY Market NIY Occupancy Covivio 39.5% 3.6% 4.69% 96.6% NSI 28.7% 4.6% 7.04% 93.8% Mercialys 35.3% 5.29% 7.27% 95.6% Wereldhave 42.4% 6.4% 7.91% 95.8% Vastned 43.4% 4.2% 5.73% 98.6% Cofinimmo 45.6% 5.3% 6.01% 98.7% Click to enlargeSource: Author calculations based on company disclosures.ConclusionsThere are several ways to group the six REITs. One approach is to look for the difference between the valuation NIY and market NIY. It is the largest at NSI - over 2% - and Mercialys.For NSI the explanation to me is a combination of low demand for office space coupled with changes to Dutch REIT legislation. The real positive is the low loan-to-value.Mercialys looks really appealing as it offers the second highest market-implied yield after Wereldhave and does not operate in the Netherlands. The loan-to-value is also the second-lowest among the group.Covivio looks unattractive to me as it has a very large office exposure of 55%  coupled with low yields. The residential portion is appealing in an economic downturn however.Wereldhave is the standout in terms of both valuation NIY and market NIY. The expected residential gains will likely offset changes in the Dutch REIT regime.Vastned looks unattractive compared to Mercialys and Wereldhave as the market yield is some 1.5-2% lower. It boasts a strong occupancy but low average debt maturity.Cofinimmo is the only healthcare player in the group with a predictable cash flow thanks to long term ageing trends. Thus despite its high leverage it is an attractive recession option.Overall  of the six REITs I would consider complementing my Wereldhave position with Mercialys  NSI and Cofinimmo.Thank you for reading.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.,neutral,0.02,0.98,0.0,mixed,0.28,0.27,0.44,True,English,"['6 European REITs', 'Metric LTV Valuation NIY Market NIY Occupancy Covivio', 'long average residual lease length', 'Valuation net initial yield', 'Vastned Q4 2022 Results Presentation', 'market-implied net initial yield', 'Covivio Q4 2022 Results Presentation', 'EPRA net initial yield', 'Mercialys Q4 2022 Results Presentation', 'Wereldhave Q4 2022 Results Presentation', 'Cofinimmo Q4 2022 Results Presentation', 'NSI Q4 2022 Results Presentation', 'out unrounded division factor', 'The EPRA NIY', 'diversified business model', 'Dutch REIT legislation', 'good development margins', 'Dutch REIT regime', 'rising interest rates', 'Net Disposal Value', 'Net asset value', 'residential development projects', 'mixed use element', 'fixed interest debt', 'fixed rate debt', 'office real estate', 'mixed use properties', 'residential real estate', 'average debt maturity', 'short company highlights', 'common metric', 'average maturity', 'net income', 'market value', 'residential use', 'office portfolio', 'retail properties', 'average cost', 'market price', 'EPRA NDV', 'value ratio', 'Andrii Yalanskyi', 'one type', 'several sectors', 'current strategy', 'share dividend', 'main headwind', 'Mercialys Mercialys', 'working spaces', 'growth opportunities', 'retail portfolio', 'main differentiator', 'direct result', 'FFO) guidance', 'economic uncertainty', 'three sectors', 'distribution networks', 'total portfolio', 'key differentiator', 'Price/NDV Ratio', 'low prices', 'P/NDV Ratio', 'Author calculations', 'several ways', 'debt reduction', 'European REITs', 'other REITs', 'six REITs', 'retail assets', 'assets ratio', 'financing cost', 'several countries', 'Comparison Table', 'One approach', 'company disclosures', '1.24% cost', '9 countries', 'Introduction', 'article', 'radar', 'others', 'exposure', 'terms', 'size', 'offices', 'hotels', '6.3 years', 'hedging', 'divestments', 'Euronext', 'Netherlands', '4.7 years', 'changes', 'effect', 'earnings', 'MEIYF', 'France', 'tenants', '4.9 years', 'minimum', 'WRDEF', 'Belgium', '3.5 years', 'hit', '2.2 years', 'CFMOF', 'healthcare', 'overview', 'option', 'shares', 'order', 'leverage', '13 years', 'focus', 'companies', 'Loan', 'proxy', 'bonds', 'example', 'time', 'writing', 'Source', 'Conclusions', 'difference', 'larges', '8', '10.4']",2023-02-26,2023-02-27,seekingalpha.com
19290,EuroNext,Bing API,https://www.finanznachrichten.de/nachrichten-2023-02/58419682-galapagos-nv-galapagos-to-present-new-data-from-long-term-extension-study-of-filgotinib-in-ulcerative-colitis-at-annual-ecco-congress-2023-399.htm,Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023,Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of JyselecaÂ® (f,"Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca Â® (filgotinib  an oral  once daily  JAK1 preferential inhibitor) will be presented(filgotinib  an oral  once daily  JAK1 preferential inhibitor) will be presented SELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC) who received filgotinib 200mg for nearly four yearsMechelen  Belgium; 27 February 2023  22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn's and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.A number of abstracts will present analyses from the SELECTION program with filgotinib. These include new analysis from the long-term extension study evaluating the safety and efficacy of filgotinib in UC for nearly four years; an analysis of the prolonged benefit of filgotinib in UC; an analysis exploring factors associated with the partial Mayo Clinic Score (pMCS) over time; and analysis of the effect of filgotinib on anaemia in UC patients.Additionally  Galapagos will present pooled data from five Phase 2/3 trials  and two long-term extension trials of filgotinib designed to further understand the safety profile of filgotinib in UC and rheumatoid arthritis (RA).""We are excited to present data from multiple studies of filgotinib in UC  including results from the SELECTIONLTE study  which has been selected amongst the top 11 oral abstracts at ECCO "" said Daniele D'Ambrosio  MD  PhD  Therapeutic Area Head  of Immunology  at Galapagos. ""These presentations capture our broad range of research and commitment to the IBD community and underscore our mission to improve patients' lives by targeting diseases with high unmet needs.""Data from the SELECTIONLTE study showed that filgotinib 200mg maintained symptomatic remission and HRQoL for up to approximately four years. Amongst subjects who completed the study  the reduction in mean pMCS in SELECTION was maintained up to LTE Week 144. In non-responders  mean pMCS decreased from LTE baseline to Week 192. The results also showed that a high proportion of completers (>80% of patients) and non-responders (>70% of patients) achieved remission according to the Inflammatory Bowel Disease Questionnaire1.The safety profile of filgotinib 200mg in the SELECTIONLTE study was generally consistent with the safety profile observed in previous SELECTION studies  with no new safety signals observed.""For healthcare professionals treating patients with this debilitating disease  the results from the SELECTION studies provide an understanding of filgotinib's long-term outcomes and help make the most appropriate choices for their patients "" said Dr. Brian G. Feagan  MD  FRCPC  Professor of Medicine  Epidemiology and Biostatistics  Western University  London  Ontario  Canada and lead investigator of the SELECTION trial. ""This latest data reinforces the positive long-term safety and efficacy profile of filgotinib  indicating its potential to be an important treatment option for people living with moderate to severe UC.""Galapagos is also hosting a hybrid symposium: 'Journey to comprehensive disease control in UC' on Thursday 2 March 2023 from 18:45-19:45 CET  which will feature experts' perspectives on what matters most to patients  and how to raise the bar when treating patients with UC. The symposium will include a mix of classical plenary lectures  including tackling challenges and misconceptions  sharing of real-world practical experience in the management of patients with UC  and the place of JAK inhibition in clinical practice.Key Abstracts:Abstract title Authors Presentation date/time Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among patients with Ulcerative Colitis: Results from the SELECTION LTE study Brian Feagan   Katsuyoshi Matsuoka  Gerhard Rogler  Margaux Faes  Alessandra Oortwijn  Angela de Haas  Christine Rudolph and Laurent Peyrin-Biroulet Oral presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0035) OP35 (https://doi.org/10.1093/ecco-jcc/jjac190.0035)Presentation date  time & location: Saturday 4 March 2023  09:50-10:00  Plenary HallSession name: Sequencing in IBD - Scientific Session 10: Evolving goals Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION David Laharie   Andreas Sturm  Taku Kobayashi  Takayuki Matsumoto  Alessandra Oortwijn  Corinne Jamoul  Margaux Faes  Angela de Haas and SÃ©verine Vermeire Poster presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0820)P690 (https://doi.org/10.1093/ecco-jcc/jjac190.0820)Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial Laurent Peyrin-Biroulet   Edouard Louis  Tadakazu Hisamatsu  Corinne Jamoul  Eva Santermans  Kristina Harris  Angela de Haas  Alessandra Oortwijn and Brian Feagan Poster presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0866) (https://doi.org/10.1093/ecco-jcc/jjac190.0866)P736 (https://doi.org/10.1093/ecco-jcc/jjac190.0866)Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION Roberta Loveikyte   Angela de Haas  Alessandra Oortwijn  Bart Eskens  Corinne Jamoul  Karine Muller and Andrea E. van der Meulen-de Jong Poster presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0523)P393 (https://doi.org/10.1093/ecco-jcc/jjac190.0523)Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme C Janneke van der Woude   Stefan Schreiber  Laurent Peyrin-Biroulet  ZoltÃ¡n Szekanecz  Ernest HS Choy  Pieter-Jan Stiers  Paul Van Hoek  Katrien Van Beneden  Angela de Haas  Christine Rudolph and Hugo ten Cate Poster presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0650)P520 (https://doi.org/10.1093/ecco-jcc/jjac190.0650)Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Investigating the symptom burden among European patients with moderate-to-severe Crohn's disease using a real-world survey Johan Burisch  Ailsa Hart  Andreas Sturm   Hannah Knight  Christine Rudolph  Rachael Meadows  Alessandra Oortwijn  Sarah Weatherby  Roger Rolph  Fatima Dawod and Alessandro Armuzzi Poster presentationPresentation number: (https://doi.org/10.1093/ecco-jcc/jjac190.0754) (https://doi.org/10.1093/ecco-jcc/jjac190.0754)P624 (https://doi.org/10.1093/ecco-jcc/jjac190.0754)Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6About ulcerative colitisUC is a debilitating inflammatory bowel disease (IBD) that occurs as a result of an abnormal immune system response. Across Europe an estimated 2.5 - 3 million people2 are affected by IBD  which includes UC and Crohn's disease (CD). UC is a chronic inflammatory condition characterized by periods of flare ups followed by remission. In addition to the physical impact from flare ups  there is also a psychological impact associated with UC. It causes significant impairments on quality of life and a poor prognosis is often seen in patients with symptoms of moderate to severe UC at diagnosis.About the SELECTION clinical programThe SELECTION program comprised of SELECTION and the associated long-term extension study (SELECTIONLTE).The SELECTION Phase 3 study was a multi-center  randomized  double-blind  placebo-controlled study designed to assess the safety and efficacy of the preferential JAK1 inhibitor filgotinib in adult patients with moderate to severe active UC. The SELECTION study (NCT02914522) comprised of two induction trials and a maintenance trial. Induction Study A enrolled biologic-naÃ¯ve patients and Induction Study B enrolled biologic-experienced patients. A majority of the patients included in the SELECTION study (n=1348) had a pMCS of 9 or higher at baseline  and 43% of biologic-experienced patients (n=297/689) had an insufficient response to a TNF antagonist and vedolizumab as well.3The primary objectives of the SELECTION clinical program were to evaluate the efficacy of filgotinib compared with a placebo in establishing clinical remission as determined by the Mayo endoscopic sub-score  rectal bleeding sub-score  and decrease in stool frequency from baseline. Patients who completed the induction and maintenance studies  patients who were not responders at Week 10  and patients with disease worsening during the maintenance study were enrolled in the ongoing SELECTIONLTE study (NCT02914535) to evaluate the long-term safety and efficacy of filgotinib in patients suffering from UC. An interim report of SELECTIONLTE assessed the safety and efficacy of open-label filgotinib through to Week 144 in completers and through to Week 192 in non-responders  respectively.About filgotinibFilgotinib is marketed as JyselecaÂ® in Europe and Japan for the treatment of adults with moderate to severe active RA who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs. Filgotinib is also marketed as JyselecaÂ® in Europe and Japan for the treatment of adult patients with moderate to severe active UC who have had an inadequate response with  lost response to  or were intolerant to either conventional therapy or a biologic agent. JyselecaÂ® 100mg and 200mg applications are registered in the above-mentioned territories.The European Summary of Product Characteristics for filgotinib  which includes contraindications and special warnings and precautions  is available at www.ema.europa.eu . The Great Britain Summary of Product Characteristics for filgotinib can be found at www.medicines.org.uk/emc and the Northern Ireland Summary of Product Characteristics for filgotinib can be found at www.emcmedicines.com/en-GB/northernireland   respectively. The interview form from the Japanese Ministry of Health  Labour and Welfare is available at www.info.pmda.go.jp .JyselecaÂ® is a trademark of Galapagos NV and Gilead Sciences  Inc. or its related companies. Except for filgotinib's approval as JyselecaÂ® for the treatment of moderate to severe active RA and UC by the relevant regulatory authorities in the European Union  Great Britain  and Japan our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering  developing  and commercializing innovative medicines. We are committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities  including small molecules and cell therapies Our portfolio comprises discovery through to commercialized programs in immunology  oncology  and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information  please visit www.glpg.com or follow us on LinkedIn or Twitter .ContactMedia relationsMarieke Vermeersch+32 479 490 603Elisa Chenailler+41 79 853 33 54HÃ©lÃ¨ne de Kruijs+31 6 22463921media@glpg.com (mailto:media@glpg.com) Investor relationsSofie Van Gijsel+1 781 296 1143Sandra Cauwenberghs+32 495 58 46 63ir@glpg.com (mailto:ir@glpg.com)Forward Looking StatementsThis press release includes forward-looking statements  all of which involve certain risks and uncertainties. These statements are often  but are not always  made through the use of words or phrases such as ""will "" ""further "" ""prolonged "" ""ongoing "" ""estimated "" ""over time "" ""long-term ""and ""consistent ""as well as similar expressions. Forward-looking statements contained in this press release include  but are not limited to  statements related to our plans and strategy with respect to the SELECTION and SELECTIONLTE study  statements related to the data and the analysis of data from the SELECTION and SELECTIONLTE study  and statements related to our plans and strategy with respect to filgotinib. We caution the reader that forward-looking statements are based on our management's current expectations and beliefs and are not guarantees of our future performance. Forward-looking statements involve known and unknown risks  uncertainties and other factors which might cause our actual results  performance or achievements to be materially different from any historic or future results  performance or achievements expressed or implied by such statements. These risks  uncertainties and other factors include  without limitation  the risk that ongoing and future clinical studies with filgotinib may not be completed in the currently envisaged timelines or at all  the inherent risks and uncertainties associated with competitive developments  clinical trials  recruitment of patients product development activities  and regulatory approval requirements (including  without limitation  that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety  efficacy or other reasons) including the filgotinib clinical program and the SELECTION and SELECTIONLTE study  the risks related to continued regulatory review of filgotinib following approval by relevant regulatory authorities  including the European Medicines Agency's safety review of JAK inhibitors used to treat certain inflammatory disorders  the risks that regulatory authorities may require additional post-approval trials of filgotinib or any of our other product candidates that may be approved in the future  our reliance on collaborations with third parties (including Gilead)  the risk that our estimations regarding our filgotinib development program and the commercial potential of filgotinib may be incorrect  the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will need to revise our business plan  and risks related to the ongoing COVID-19 pandemic. A further list and description of these risks  uncertainties  and other risks can be found in our filings and reports with the U.S. Securities and Exchange Commission (""SEC"")  including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. In addition  even if our results  performance or achievements are consistent with such forward-looking statements  they may not be predictive of results  performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this press release unless required by law or regulation.1 The Inflammatory Bowel Disease Questionnaire is a widely used questionnaire for HRQoL assessment in patients with inflammatory bowel diseases.2 Burisch J. et al. Journal of Crohn's and Colitis 2013; 7:322-337.3 Feagan et al.  Lancet 2021; 397: 2372-84.Attachment",neutral,0.0,1.0,0.0,positive,0.69,0.28,0.03,True,English,"['long-term extension study', 'annual ECCO congress', 'new data', 'ulcerative colitis', 'Galapagos NV', 'filgotinib', 'partial Mayo Clinic Score', 'five Phase 2/3 trials', 'two long-term extension trials', 'Dr. Brian G. Feagan', 'Plenary Hall Session name', 'Inflammatory Bowel Disease Questionnaire', 'Laurent Peyrin-Biroulet Oral presentation', 'severe active ulcerative colitis', 'classical plenary lectures', 'JAK1 preferential inhibitor', ""Daniele D'Ambrosio"", 'Therapeutic Area Head', 'real-world practical experience', 'Abstract title Authors', 'Angela de Haas', 'SÃ©verine Vermeire', 'comprehensive disease control', 'SELECTION long-term extension', 'long-term extension study', 'high unmet needs', 'Hall B5&6 Factors', 'SELECTION David Laharie', 'positive long-term safety', 'top 11 oral abstracts', 'important treatment option', 'previous SELECTION studies', 'symptomatic remission rates', 'new safety signals', 'consistent safety profile', 'Presentation date/time Efficacy', 'SELECTION LTE study', 'Brian Feagan', 'Phase 3 SELECTION', 'oral, once', 'long-term outcomes', 'Scientific Session', 'debilitating disease', 'LTE) studies', 'high proportion', 'Poster presentation', 'Colitis Organization', 'SELECTION program', 'SELECTION trial', 'multiple studies', 'LTE baseline', 'safety outcomes', 'efficacy profile', 'severe UC', 'Presentation number', 'health-related quality', 'European Crohn', 'annual congress', 'prolonged benefit', 'rheumatoid arthritis', 'broad range', 'healthcare professionals', 'appropriate choices', 'Western University', 'lead investigator', ""experts' perspectives"", 'JAK inhibition', 'clinical practice', 'Key Abstracts', 'Katsuyoshi Matsuoka', 'Gerhard Rogler', 'Margaux Faes', 'Alessandra Oortwijn', 'Christine Rudolph', 'Evolving goals', 'Andreas Sturm', 'Taku Kobayashi', 'Takayuki Matsumoto', 'Corinne Jamoul', 'Poster Exhibition', 'SELECTIONLTE study', 'New analyses', 'four years', 'LTE Week', 'IBD) community', 'moderate to', 'IBD community', 'new data', 'Six presentations', '1-4 March', 'new analysis', 'hybrid symposium', 'Thursday 2 March', 'Galapagos NV', 'latest data', 'mean pMCS', 'filgotinib 200mg', ""patients' lives"", ""Galapagos' commitment"", 'UC patients', '~4 years', 'Jyseleca Â®', 'life', 'HRQoL', 'Mechelen', 'Belgium', '27 February', 'Euronext', 'NASDAQ', 'GLPG', 'ECCO', 'place', 'effect', 'anaemia', 'results', 'MD', 'PhD', 'Immunology', 'research', 'diseases', 'up', 'subjects', 'reduction', 'responders', 'completers', 'understanding', 'FRCPC', 'Professor', 'Medicine', 'Epidemiology', 'Biostatistics', 'London', 'Ontario', 'Canada', 'potential', 'people', 'Journey', 'CET', 'bar', 'mix', 'challenges', 'misconceptions', 'management', 'jcc', 'location', 'Saturday', 'Sequencing', 'Friday']",2023-02-05,2023-02-27,finanznachrichten.de
19291,EuroNext,Bing API,https://finance.yahoo.com/news/argenx-appoints-steve-krognes-board-210100526.html,argenx Appoints Steve Krognes to Board of Directors,Amsterdam  the Netherlands â€“  (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET ,argenx SEFebruary 27  2023Amsterdam  the Netherlands â€“ argenx SE (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET  Steve Krognes was appointed as a non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance Committee.As a result of the appointment of Mr. Krognes  Werner Lanthaler has formally resigned as non-executive director of the Board of Directors and chairperson of the Audit and Compliance Committee to enable this important step in long-term succession planning.â€œWe welcome Steve to the Board and are confident that with his strong financial and compliance expertise and valuable industry knowledge  he possesses the ideal profile to support argenx on our innovative  entrepreneurial mission â€ said Tim Van Hauwermeiren  Chief Executive Officer of argenx. â€œI would also like to express my gratitude to Werner for his substantial contributions over the last eight years. His entrepreneurial spirit combined with his broad experience in finance and executive leadership within biopharma has helped guide us from a research and development company to a fully integrated  global immunology company.â€The voting result and all documents relating to the shareholdersâ€™ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP)  argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S.  the EU and Japan. For more information  visit www.argenx.com and follow us on LinkedIn  Twitter  and Instagram.Story continuesFor further information  please contact:Media:Erin Murphyemurphy@argenx.comInvestors:Beth DelGiaccobdelgiacco@argenx.com,neutral,0.01,0.98,0.0,positive,0.82,0.16,0.03,True,English,"['Steve Krognes', 'argenx', 'Board', 'Directors', 'integrated, global immunology company', 'severe autoimmune diseases', 'long-term succession planning', 'valuable industry knowledge', 'innovative, entrepreneurial mission', 'Tim Van Hauwermeiren', 'last eight years', 'leading academic researchers', 'Immunology Innovation Program', 'novel antibody-based medicines', 'neonatal Fc receptor', 'extraordinary general meeting', 'Chief Executive Officer', 'development company', 'immunology breakthroughs', 'executive director', 'executive leadership', 'Compliance Committee', 'Mr. Krognes', 'important step', 'strong financial', 'compliance expertise', 'ideal profile', 'substantial contributions', 'broad experience', 'shareholdersâ€™ meeting', 'world-class portfolio', 'FcRn) blocker', 'U.S.', 'Erin Murphy', 'Beth DelGiacco', 'Steve Krognes', 'Werner Lanthaler', 'voting result', 'argenx SE', 'argenx website', 'February', 'Amsterdam', 'Netherlands', 'Euronext', 'Nasdaq', 'ARGX', 'lives', 'people', 'Board', 'Directors', 'chairperson', 'Audit', 'appointment', 'gratitude', 'spirit', 'finance', 'biopharma', 'documents', 'investors/shareholder-meetings', 'IIP', 'Japan', 'information', 'LinkedIn', 'Twitter', 'Instagram', 'Story', 'Media', 'bdelgiacco', '12:00']",2023-02-27,2023-02-27,finance.yahoo.com
19292,EuroNext,Bing API,https://finance.yahoo.com/news/galapagos-present-data-long-term-210100805.html,Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023,Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohnâ€™s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023. A number of abstracts will present analyses from the SELECTION program with filgotinib.,Galapagos NVSix presentations demonstrate Galapagosâ€™ commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca Â® (filgotinib  an oral  once daily  JAK1 preferential inhibitor) will be presentedSELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC) who received filgotinib 200mg for nearly four yearsMechelen  Belgium; 27 February 2023  22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohnâ€™s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.A number of abstracts will present analyses from the SELECTION program with filgotinib. These include new analysis from the long-term extension study evaluating the safety and efficacy of filgotinib in UC for nearly four years; an analysis of the prolonged benefit of filgotinib in UC; an analysis exploring factors associated with the partial Mayo Clinic Score (pMCS) over time; and analysis of the effect of filgotinib on anaemia in UC patients.Additionally  Galapagos will present pooled data from five Phase 2/3 trials  and two long-term extension trials of filgotinib designed to further understand the safety profile of filgotinib in UC and rheumatoid arthritis (RA).â€œWe are excited to present data from multiple studies of filgotinib in UC  including results from the SELECTIONLTE study  which has been selected amongst the top 11 oral abstracts at ECCO â€ said Daniele Dâ€™Ambrosio  MD  PhD  Therapeutic Area Head  of Immunology  at Galapagos. â€œThese presentations capture our broad range of research and commitment to the IBD community and underscore our mission to improve patientsâ€™ lives by targeting diseases with high unmet needs.â€Data from the SELECTIONLTE study showed that filgotinib 200mg maintained symptomatic remission and HRQoL for up to approximately four years. Amongst subjects who completed the study  the reduction in mean pMCS in SELECTION was maintained up to LTE Week 144. In non-responders  mean pMCS decreased from LTE baseline to Week 192. The results also showed that a high proportion of completers (>80% of patients) and non-responders (>70% of patients) achieved remission according to the Inflammatory Bowel Disease Questionnaire1.Story continuesThe safety profile of filgotinib 200mg in the SELECTIONLTE study was generally consistent with the safety profile observed in previous SELECTION studies  with no new safety signals observed.â€œFor healthcare professionals treating patients with this debilitating disease  the results from the SELECTION studies provide an understanding of filgotinibâ€™s long-term outcomes and help make the most appropriate choices for their patients â€ said Dr. Brian G. Feagan  MD  FRCPC  Professor of Medicine  Epidemiology and Biostatistics  Western University  London  Ontario  Canada and lead investigator of the SELECTION trial. â€œThis latest data reinforces the positive long-term safety and efficacy profile of filgotinib  indicating its potential to be an important treatment option for people living with moderate to severe UC.â€Galapagos is also hosting a hybrid symposium: â€˜Journey to comprehensive disease control in UCâ€™ on Thursday 2 March 2023 from 18:45-19:45 CET  which will feature expertsâ€™ perspectives on what matters most to patients  and how to raise the bar when treating patients with UC. The symposium will include a mix of classical plenary lectures  including tackling challenges and misconceptions  sharing of real-world practical experience in the management of patients with UC  and the place of JAK inhibition in clinical practice.Key Abstracts:Abstract title Authors Presentation date/time Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among patients with Ulcerative Colitis: Results from the SELECTION LTE study Brian Feagan   Katsuyoshi Matsuoka  Gerhard Rogler  Margaux Faes  Alessandra Oortwijn  Angela de Haas  Christine Rudolph and Laurent Peyrin-Biroulet Oral presentationPresentation number: OP35Presentation date  time & location: Saturday 4 March 2023  09:50-10:00  Plenary HallSession name: Sequencing in IBD - Scientific Session 10: Evolving goals Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION David Laharie   Andreas Sturm  Taku Kobayashi  Takayuki Matsumoto  Alessandra Oortwijn  Corinne Jamoul  Margaux Faes  Angela de Haas and SÃ©verine Vermeire Poster presentationPresentation number: P690Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial Laurent Peyrin-Biroulet   Edouard Louis  Tadakazu Hisamatsu  Corinne Jamoul  Eva Santermans  Kristina Harris  Angela de Haas  Alessandra Oortwijn and Brian Feagan Poster presentationPresentation number: P736Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION Roberta Loveikyte   Angela de Haas  Alessandra Oortwijn  Bart Eskens  Corinne Jamoul  Karine Muller and Andrea E. van der Meulen-de Jong Poster presentationPresentation number: P393Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme C Janneke van der Woude   Stefan Schreiber  Laurent Peyrin-Biroulet  ZoltÃ¡n Szekanecz  Ernest HS Choy  Pieter-Jan Stiers  Paul Van Hoek  Katrien Van Beneden  Angela de Haas  Christine Rudolph and Hugo ten Cate Poster presentationPresentation number: P520Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6 Investigating the symptom burden among European patients with moderate-to-severe Crohnâ€™s disease using a real-world survey Johan Burisch  Ailsa Hart  Andreas Sturm   Hannah Knight  Christine Rudolph  Rachael Meadows  Alessandra Oortwijn  Sarah Weatherby  Roger Rolph  Fatima Dawod and Alessandro Armuzzi Poster presentationPresentation number: P624Presentation date  time & location: Friday 3 March 2023  12:30-13:30  Poster Exhibition  Hall B5&6About ulcerative colitisUC is a debilitating inflammatory bowel disease (IBD) that occurs as a result of an abnormal immune system response. Across Europe an estimated 2.5 - 3 million people2 are affected by IBD  which includes UC and Crohnâ€™s disease (CD). UC is a chronic inflammatory condition characterized by periods of flare ups followed by remission. In addition to the physical impact from flare ups  there is also a psychological impact associated with UC. It causes significant impairments on quality of life and a poor prognosis is often seen in patients with symptoms of moderate to severe UC at diagnosis.About the SELECTION clinical programThe SELECTION program comprised of SELECTION and the associated long-term extension study (SELECTIONLTE).The SELECTION Phase 3 study was a multi-center  randomized  double-blind  placebo-controlled study designed to assess the safety and efficacy of the preferential JAK1 inhibitor filgotinib in adult patients with moderate to severe active UC. The SELECTION study (NCT02914522) comprised of two induction trials and a maintenance trial. Induction Study A enrolled biologic-naÃ¯ve patients and Induction Study B enrolled biologic-experienced patients. A majority of the patients included in the SELECTION study (n=1348) had a pMCS of 9 or higher at baseline  and 43% of biologic-experienced patients (n=297/689) had an insufficient response to a TNF antagonist and vedolizumab as well.3The primary objectives of the SELECTION clinical program were to evaluate the efficacy of filgotinib compared with a placebo in establishing clinical remission as determined by the Mayo endoscopic sub-score  rectal bleeding sub-score  and decrease in stool frequency from baseline. Patients who completed the induction and maintenance studies  patients who were not responders at Week 10  and patients with disease worsening during the maintenance study were enrolled in the ongoing SELECTIONLTE study (NCT02914535) to evaluate the long-term safety and efficacy of filgotinib in patients suffering from UC. An interim report of SELECTIONLTE assessed the safety and efficacy of open-label filgotinib through to Week 144 in completers and through to Week 192 in non-responders  respectively.About filgotinibFilgotinib is marketed as JyselecaÂ® in Europe and Japan for the treatment of adults with moderate to severe active RA who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs. Filgotinib is also marketed as JyselecaÂ® in Europe and Japan for the treatment of adult patients with moderate to severe active UC who have had an inadequate response with  lost response to  or were intolerant to either conventional therapy or a biologic agent. JyselecaÂ® 100mg and 200mg applications are registered in the above-mentioned territories.The European Summary of Product Characteristics for filgotinib  which includes contraindications and special warnings and precautions  is available at www.ema.europa.eu . The Great Britain Summary of Product Characteristics for filgotinib can be found at www.medicines.org.uk/emc and the Northern Ireland Summary of Product Characteristics for filgotinib can be found at www.emcmedicines.com/en-GB/northernireland   respectively. The interview form from the Japanese Ministry of Health  Labour and Welfare is available at www.info.pmda.go.jp .JyselecaÂ® is a trademark of Galapagos NV and Gilead Sciences  Inc. or its related companies. Except for filgotinibâ€™s approval as JyselecaÂ® for the treatment of moderate to severe active RA and UC by the relevant regulatory authorities in the European Union  Great Britain  and Japan  our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering  developing  and commercializing innovative medicines. We are committed to improving patientsâ€™ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities  including small molecules and cell therapies Our portfolio comprises discovery through to commercialized programs in immunology  oncology  and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information  please visit www.glpg.com or follow us on LinkedIn or Twitter .ContactMedia relationsMarieke Vermeersch+32 479 490 603Elisa Chenailler+41 79 853 33 54HÃ©lÃ¨ne de Kruijs+31 6 22463921media@glpg.com Investor relationsSofie Van Gijsel+1 781 296 1143Sandra Cauwenberghs+32 495 58 46 63ir@glpg.comForward Looking StatementsThis press release includes forward-looking statements  all of which involve certain risks and uncertainties. These statements are often  but are not always  made through the use of words or phrases such as â€œwill â€ â€œfurther â€ â€œprolonged â€ â€œongoing â€ â€œestimated â€ â€œover time â€ â€œlong-term â€ and â€œconsistent â€ as well as similar expressions. Forward-looking statements contained in this press release include  but are not limited to  statements related to our plans and strategy with respect to the SELECTION and SELECTIONLTE study  statements related to the data and the analysis of data from the SELECTION and SELECTIONLTE study  and statements related to our plans and strategy with respect to filgotinib. We caution the reader that forward-looking statements are based on our managementâ€™s current expectations and beliefs and are not guarantees of our future performance. Forward-looking statements involve known and unknown risks  uncertainties and other factors which might cause our actual results  performance or achievements to be materially different from any historic or future results  performance or achievements expressed or implied by such statements. These risks  uncertainties and other factors include  without limitation  the risk that ongoing and future clinical studies with filgotinib may not be completed in the currently envisaged timelines or at all  the inherent risks and uncertainties associated with competitive developments  clinical trials  recruitment of patients  product development activities  and regulatory approval requirements (including  without limitation  that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety  efficacy or other reasons)  including the filgotinib clinical program and the SELECTION and SELECTIONLTE study  the risks related to continued regulatory review of filgotinib following approval by relevant regulatory authorities  including the European Medicines Agencyâ€™s safety review of JAK inhibitors used to treat certain inflammatory disorders  the risks that regulatory authorities may require additional post-approval trials of filgotinib or any of our other product candidates that may be approved in the future  our reliance on collaborations with third parties (including Gilead)  the risk that our estimations regarding our filgotinib development program and the commercial potential of filgotinib may be incorrect  the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will need to revise our business plan  and risks related to the ongoing COVID-19 pandemic. A further list and description of these risks  uncertainties  and other risks can be found in our filings and reports with the U.S. Securities and Exchange Commission (â€œSECâ€)  including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. In addition  even if our results  performance or achievements are consistent with such forward-looking statements  they may not be predictive of results  performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this press release unless required by law or regulation.1 The Inflammatory Bowel Disease Questionnaire is a widely used questionnaire for HRQoL assessment in patients with inflammatory bowel diseases.2 Burisch J. et al. Journal of Crohnâ€™s and Colitis 2013; 7:322-337.3 Feagan et al.  Lancet 2021; 397: 2372â€“84.Attachment,neutral,0.0,1.0,0.0,positive,0.68,0.3,0.02,True,English,"['long-term extension study', 'annual ECCO congress', 'new data', 'ulcerative colitis', 'Galapagos', 'filgotinib', 'moderate to severe active ulcerative colitis', 'partial Mayo Clinic Score', 'five Phase 2/3 trials', 'two long-term extension trials', 'Inflammatory Bowel Disease Questionnaire', 'Dr. Brian G. Feagan', 'Laurent Peyrin-Biroulet Oral presentation', 'JAK1 preferential inhibitor', 'Daniele Dâ€™Ambrosio', 'Therapeutic Area Head', 'real-world practical experience', 'Abstract title Authors', 'Angela de Haas', 'SÃ©verine Vermeire', 'comprehensive disease control', 'SELECTION long-term extension', 'long-term extension study', 'high unmet needs', 'classical plenary lectures', 'SELECTION David Laharie', 'positive long-term safety', 'top 11 oral abstracts', 'important treatment option', '2b/3 SELECTION trial', 'previous SELECTION studies', 'symptomatic remission rates', 'new safety signals', 'Hall B5&6 Factors', 'consistent safety profile', 'Presentation date/time Efficacy', 'SELECTION LTE study', 'Brian Feagan', 'severe UC', 'oral, once', 'long-term outcomes', 'Plenary Hall', 'Colitis Organization', 'debilitating disease', 'Phase 3 SELECTION', 'LTE) studies', 'high proportion', 'SELECTION program', 'Poster presentation', 'multiple studies', 'LTE baseline', 'safety outcomes', 'efficacy profile', 'Presentation number', 'health-related quality', 'European Crohn', 'annual congress', 'prolonged benefit', 'rheumatoid arthritis', 'broad range', 'healthcare professionals', 'appropriate choices', 'Western University', 'lead investigator', 'expertsâ€™ perspectives', 'JAK inhibition', 'clinical practice', 'Key Abstracts', 'Katsuyoshi Matsuoka', 'Gerhard Rogler', 'Margaux Faes', 'Alessandra Oortwijn', 'Christine Rudolph', 'Session name', 'Scientific Session', 'Evolving goals', 'Andreas Sturm', 'Taku Kobayashi', 'Takayuki Matsumoto', 'Corinne Jamoul', 'Poster Exhibition', 'Edouard Louis', 'Tadakazu Hisamatsu', 'Eva Santermans', 'Kristina Harris', 'SELECTIONLTE study', 'New analyses', 'four years', 'LTE Week', 'IBD) community', 'IBD community', 'new data', 'Galapagos NV', 'Six presentations', '1-4 March', 'new analysis', 'hybrid symposium', 'Thursday 2 March', 'latest data', 'mean pMCS', 'filgotinib 200mg', 'patientsâ€™ lives', 'Galapagosâ€™ commitment', 'UC patients', '~4 years', 'Jyseleca Â®', 'life', 'HRQoL', 'Mechelen', 'Belgium', '27 February', 'NASDAQ', 'GLPG', 'ECCO', 'place', 'effect', 'anaemia', 'results', 'MD', 'Immunology', 'research', 'diseases', 'subjects', 'reduction', 'responders', 'completers', 'Story', 'understanding', 'FRCPC', 'Professor', 'Medicine', 'Epidemiology', 'Biostatistics', 'London', 'Ontario', 'Canada', 'potential', 'people', 'Journey', 'bar', 'mix', 'challenges', 'misconceptions', 'management', 'location', 'Saturday', 'Sequencing', 'P690', 'Friday']",2023-02-27,2023-02-27,finance.yahoo.com
19293,EuroNext,Bing API,https://markets.businessinsider.com/news/stocks/eqs-news-pyrum-innovations-ag-chairman-of-the-supervisory-board-increases-his-shareholding-in-the-company-1032128644,EQS-News: Pyrum Innovations AG: Chairman of the Supervisory Board increases his shareholding in the company,Dillingen / Saar  27 February 2023 Alf Schmidt  long-time Chairman of the Supervisory Board of Pyrum Innovations AG (Pyrum  the company  ISIN: DE000A2G8ZX8)  has increased his shareholding in the Company by 1 ,EQS-News: Pyrum Innovations AG / Key word(s): MiscellaneousPyrum Innovations AG: Chairman of the Supervisory Board increases his shareholding in the company27.02.2023 / 19:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Pyrum Innovations AG: Chairman of the Supervisory Board increases his shareholding in the companyDillingen / Saar  27 February 2023 Alf Schmidt  long-time Chairman of the Supervisory Board of Pyrum Innovations AG (Pyrum  the company  ISIN: DE000A2G8ZX8)  has increased his shareholding in the Company by 1 667 shares. Due to the tight market for Pyrum shares  Pascal Klein  CEO and largest single shareholder of the company  provided shares from his holdings for this purpose. The transaction was executed as an OTC transaction at a purchase price of EUR 60.00 per share and thus around 3% above the average value of the last five trading days on Xetra (EUR 58.05).Pascal Klein  CEO of Pyrum Innovations AG: We are delighted that our very respected Chairman of the Supervisory Board has become even more invested in Pyrum. Alf Schmidt's financial commitment of around EUR 100 000 once again illustrates his firm belief in our business model and our huge potential to establish a sustainable circular economy for end-of-life tyres.Pyrum Innovations AG  a pioneer in the sustainable recycling of end-of-life tyres based on its patented pyrolysis technology  has been listed on the Euronext Growth market segment of the Oslo Stock Exchange since 30 September 2021 and on the Scale market segment of the Frankfurt Stock Exchange since 30 March 2022. In addition to the founding partners Pascal Klein and Michael Kapf  the chemical group and cooperation partner BASF is also among the major shareholders with a current share of 7.9%. In addition  the tyre manufacturer Continental  among others  also participated in the IPO.The relevant notifications of Pyrum Innovations AG on directors' dealings pursuant to Art. 19 of the Market Abuse Regulation are available on the company's website at https://www.pyrum.net/en/investors/financial-releases/regulatory-announcements/.About Pyrum Innovations AGPyrum Innovations AG is active in the attractive recycling market for end-of-life tyres with its patented pyrolysis technology. Pyrum's pyrolysis process is energy self-sufficient and  according to the Fraunhofer Institute  saves significantly more CO 2 emissions than today's standard recycling processes for end-of-life tyres - especially compared to incineration in cement plants - and produces new raw materials such as pyrolysis oil  gas and recovered carbon black from the waste used as input materials. In this way  Pyrum closes the recyclable material loop and pursues a completely sustainable business model. As a pioneer  Pyrum Innovations AG was the first company in the end-of-life tyre recycling sector to receive REACH registration from the European Chemicals Agency (ECHA) for the pyrolysis oil it produces. This means that the oil is recognised as an official raw material that can be used in production processes. In addition  Pyrum has received ISCC PLUS certification for the pyrolysis oil and the recovered carbon black. Both products are thus considered sustainable and renewable raw materials. These achievements have also been recognised by international experts in the tyre industry. For example  Pyrum won the Best Tyre Recycling Innovation category at the inaugural Recircle Awards and has been nominated for the Grand Prix Mittelstand (GroÃŸer Preis des Mittelstandes) from the German state of Saarland.https://www.pyrum.net/enContactIR.on AGFrederic HilkePhone: +49 221 9140 970Email: pyrum@ir-on.comPyrum Innovations AGDieselstr. 866763 Dillingen / SaarEmail: presse@pyrum.net,neutral,0.01,0.99,0.0,positive,0.98,0.02,0.0,True,English,"['Pyrum Innovations AG', 'Supervisory Board', 'EQS-News', 'Chairman', 'shareholding', 'company', 'Best Tyre Recycling Innovation category', 'last five trading days', 'Euronext Growth market segment', 'life tyre recycling sector', 'Pyrum Innovations AG Dieselstr.', 'Scale market segment', 'attractive recycling market', 'IR.on AG', 'largest single shareholder', 'Oslo Stock Exchange', 'Frankfurt Stock Exchange', 'Market Abuse Regulation', 'recyclable material loop', 'European Chemicals Agency', 'ISCC PLUS certification', 'inaugural Recircle Awards', 'Grand Prix Mittelstand', 'GroÃŸer Preis', 'standard recycling processes', 'sustainable circular economy', 'official raw material', 'new raw materials', 'sustainable business model', 'sustainable recycling', 'tight market', 'production processes', 'life tyres', 'input materials', 'pyrum.net', 'Key word', 'Supervisory Board', 'Alf Schmidt', 'Pascal Klein', 'purchase price', 'average value', 'financial commitment', 'firm belief', 'huge potential', 'pyrolysis technology', 'founding partners', 'Michael Kapf', 'chemical group', 'cooperation partner', 'major shareholders', 'relevant notifications', 'pyrolysis process', 'Fraunhofer Institute', 'CO 2 emissions', 'cement plants', 'carbon black', 'REACH registration', 'international experts', 'German state', 'Frederic Hilke', 'pyrolysis oil', 'OTC transaction', 'current share', 'Pyrum shares', 'long-time Chairman', 'first company', '1,667 shares', 'EQS-News', 'Miscellaneous', 'shareholding', '19:00 CET', 'CEST', 'issuer', 'content', 'announcement', 'Dillingen', 'Saar', 'ISIN', 'CEO', 'holdings', 'purpose', 'Xetra', 'respected', 'end', 'pioneer', '30 September', '30 March', 'addition', 'BASF', 'manufacturer', 'Continental', 'others', 'IPO', 'directors', 'dealings', 'Art.', 'website', 'investors', 'financial-releases', 'incineration', 'gas', 'waste', 'way', 'ECHA', 'products', 'achievements', 'industry', 'example', 'Mittelstandes', 'Contact', 'Phone', 'Email', 'presse']",2023-02-27,2023-02-27,markets.businessinsider.com
19294,EuroNext,Bing API,https://www.risk.net/derivatives/7956122/mts-and-wematch-combine-to-launch-euro-swap-mtf,MTS and WeMatch combine to launch euro swap MTF,European government bond venue MTS has entered the interest rate swap market  teaming up with fintech firm WeMatch to launch a venue that will start with the interdealer market  before expanding to the dealer-to-client sector within the next year.,European government bond venue MTS has entered the interest rate swap market  teaming up with fintech firm WeMatch to launch a venue that will start with the interdealer market  before expanding to the dealer-to-client sector within the next year.The Euronext-owned venue switched on the MTS Swaps multilateral trading facility (MTF) this morning (February 27). It goes live with around 10 dealers  offering euro interest rate swaps trading using WeMatchâ€™s technology.Once that has bedded in  MTS,neutral,0.01,0.99,0.0,neutral,0.0,1.0,0.0,True,English,"['euro swap', 'MTS', 'WeMatch', 'MTF', 'MTS Swaps multilateral trading facility', 'euro interest rate swaps', 'interest rate swap market', 'European government bond venue', 'The Euronext-owned venue', 'interdealer market', 'fintech firm', 'client sector', 'next year', 'WeMatch', 'MTF', 'February', '10 dealers', 'technology']",2023-02-27,2023-02-27,risk.net
19295,EuroNext,Bing API,https://www.actusnews.com/en/hdf-energy/pr/2023/02/27/strong-commercial-rollout-in-line-with-strategic-plan,Strong commercial rollout in line with strategic plan,HydrogÃ¨ne de France (â€œHDF Energyâ€ or the â€œCompanyâ€ â€“ Euronext Paris: HDF)  a global pioneer in high-power hydrogen power plants  presents its business activity and revenues for the 2022 financial year.,27/02/2023 - 18:00Bordeaux  27 February 2023 â€“ HydrogÃ¨ne de France (â€œHDF Energyâ€ or the â€œCompanyâ€ â€“ Euronext Paris: HDF)  a global pioneer in high-power hydrogen power plants  presents its business activity and revenues for the 2022 financial year.Solid project portfolioPlant MW Storage MWh Development 751 2 019 Prospecting 1 942 2 754Commercial rollout remained the Group's main focus in 2022. The deployment of strong teams comprising 48 developers across all target regions (versus 23 at 31 December 2021) has allowed the Company to build a solid portfolio of large-scale projects and partnerships at 31 December 2022. As a result  the capacity of power plants in development phase in the portfolio was up by more than 25% compared with December 31  2021.Portfolio monitoring provides the earliest indicator of HDF's value creation for both the Group and all project stakeholders. HDF estimates that it is able to generate revenues representing between 12% and 17% of the cost of construction during the development and construction phases  including provision of engineering services and supply of fuel cells during the power plant construction phase.Strong revenue growth in 2022Consolidated revenues for 2022 totalled â‚¬3.5 million versus â‚¬0.9 million in 2021.This includes â‚¬3.0 million recognised under the development contract for the Renewstable Barbados (RSB) project since February 2022  when the Rubis Group became RSB's majority shareholder.Invoicing issued by HDF in 2022 for project management assistance services for projects over which the Group retains control as of end of 2022  the impact of which is eliminated in the consolidated financial statements  amounted to â‚¬3.0 million in 2022. This value creation initially eliminated in the consolidated financial statements will be recognised indirectly through gains or losses on disposal of the investments when control is lost.Continuation of the development planThe Group reached a new milestone on 24 February 2023 by officially launching the construction of the Blanquefort plant for the mass production of high-power fuel cells. The plant is expected to start operating in 2024 and to contribute towards achieving the Group's ambitions.Damien Havard  Chairman and CEO of HydrogÃ¨ne de France  said:â€œIn line with our strategic plan  in 2022 we stepped up the drive to strengthen and structure our teams across all our regions. Having 48 experienced developers worldwide gives HDF the ability to implement its action plan. We have also made very concrete and material progress in all our regions this year. We are extremely keen and proud to see our projects supported at all levels and to make a tangible contribution to the energy transition.â€ABOUT HDF ENERGYHDF Energy is a global pioneer in high-power hydrogen power plants. The Company designs and develops power plants that generate non-intermittent  non-polluting renewable energy  day and night. In addition  HDF Energy organises the financing  construction and operation of these power plants through SPVs.HDF is the designer of RenewstableÂ®  its flagship model of multi-megawatt power plants producing firm power from an intermittent renewable energy source (wind or solar) and massive energy storage in the form of green hydrogen generated on site.HDF Energy is also an industrial company which will mass produce  from 2024  the most strategic component of its power plants - high-power fuel cells - in its plant near Bordeaux. Already a major supplier of electricity for energy grids  this industrial activity will also allow HDF Energy to serve the heavy marine and rail mobility markets. Alongside its strategic partners  the Company develops projects involving hydrogen-powered freight locomotives and large vessel propulsion and auxiliary power systems.The Company operates on five continents and is developing a business portfolio currently worth over â‚¬5 billion.HDF Energy is listed in Euronext Compartment B.Read the financial information on HydrogÃ¨ne de France here:www.hdf-energy.comContacts,positive,0.99,0.01,0.0,mixed,0.73,0.02,0.25,True,English,"['Strong commercial rollout', 'strategic plan', 'line', 'Solid project portfolio Plant MW Storage MWh Development', 'project management assistance services', 'intermittent, non-polluting renewable energy', 'intermittent renewable energy source', 'high-power hydrogen power plants', 'HydrogÃ¨ne de France', 'massive energy storage', 'power plant construction phase', 'rail mobility markets', 'hydrogen-powered freight locomotives', 'large vessel propulsion', 'high-power fuel cells', 'auxiliary power systems', 'multi-megawatt power plants', 'Strong revenue growth', 'Euronext Compartment B.', 'consolidated financial statements', 'solid portfolio', 'development phase', 'project stakeholders', 'RSB) project', 'green hydrogen', 'Blanquefort plant', 'Portfolio monitoring', 'engineering services', 'development contract', 'development plan', 'business portfolio', 'firm power', 'Euronext Paris', '2022 financial year', 'financial information', 'energy transition', 'energy grids', 'global pioneer', 'business activity', 'Commercial rollout', 'main focus', 'strong teams', 'earliest indicator', 'value creation', 'Consolidated revenues', 'majority shareholder', 'new milestone', 'mass production', 'Damien Havard', 'strategic plan', 'action plan', 'material progress', 'tangible contribution', 'flagship model', 'strategic component', 'major supplier', 'industrial activity', 'heavy marine', 'strategic partners', 'five continents', 'HDF Energy', 'construction phases', 'Renewstable Barbados', '48 experienced developers', 'The Company', 'industrial company', 'target regions', 'Rubis Group', 'The Group', 'large-scale projects', '48 developers', 'RenewstableÂ®', 'Bordeaux', 'deployment', '31 December', 'partnerships', 'result', 'capacity', 'cost', 'provision', 'supply', 'February', 'Invoicing', 'control', 'end', 'impact', 'gains', 'losses', 'disposal', 'investments', 'Continuation', 'ambitions', 'Chairman', 'CEO', 'line', 'drive', 'ability', 'concrete', 'levels', 'night', 'addition', 'financing', 'operation', 'SPVs', 'designer', 'wind', 'solar', 'site', 'produce', 'electricity', 'Contacts', '27']",2023-02-27,2023-02-27,actusnews.com
19296,EuroNext,Twitter API,Twitter,@KPITALISME euronext,nan,@KPITALISME euronext,neutral,0.23,0.76,0.02,neutral,0.23,0.76,0.02,True,English,"['KPITALISME', 'KPITALISME']",2023-02-27,2023-02-27,Unknown
19297,EuroNext,Twitter API,Twitter,METABOLIC EXPLORER And DLTX On The List Of Winners And Losers Of Monday's Euronext Sessionhttps://t.co/nRJa6tHGhQâ€¦ https://t.co/ZmZjuCGCif,nan,METABOLIC EXPLORER And DLTX On The List Of Winners And Losers Of Monday's Euronext Sessionhttps://t.co/nRJa6tHGhQâ€¦ https://t.co/ZmZjuCGCif,neutral,0.09,0.86,0.05,neutral,0.09,0.86,0.05,True,English,"['METABOLIC EXPLORER', 'Euronext Session', 'DLTX', 'List', 'Winners', 'Losers', 'Monday', 'ZmZjuCGCif', 'METABOLIC EXPLORER', 'Euronext Session', 'DLTX', 'List', 'Winners', 'Losers', 'Monday', 'ZmZjuCGCif']",2023-02-27,2023-02-27,Unknown
19298,EuroNext,Twitter API,Twitter,@MyInvestorES Acciones de BME Growth  Euronextâ€¦,nan,@MyInvestorES Acciones de BME Growth  Euronextâ€¦,neutral,0.17,0.82,0.0,neutral,0.17,0.82,0.0,True,English,"['BME Growth', 'Acciones', 'Euronext', 'BME Growth', 'Acciones', 'Euronext']",2023-02-27,2023-02-27,Unknown
19299,EuroNext,Twitter API,Twitter,UPDATE 1-Lottomatica's shareholders approve listing at Euronext Milan $APO https://t.co/9krPcbfXeG,nan,UPDATE 1-Lottomatica's shareholders approve listing at Euronext Milan $APO https://t.co/9krPcbfXeG,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Euronext Milan', 'UPDATE', '1-Lottomatica', 'shareholders', 'listing', 'Euronext Milan', 'UPDATE', '1-Lottomatica', 'shareholders', 'listing']",2023-02-27,2023-02-27,Unknown
19300,EuroNext,Twitter API,Twitter,Euronext cautious on Allfunds acquisition  deal by no means certain https://t.co/KYTQshakjQ,nan,Euronext cautious on Allfunds acquisition  deal by no means certain https://t.co/KYTQshakjQ,neutral,0.07,0.83,0.1,neutral,0.07,0.83,0.1,True,English,"['Allfunds acquisition', 'Euronext', 'means', 'KYTQshakjQ', 'Allfunds acquisition', 'Euronext', 'means', 'KYTQshakjQ']",2023-02-27,2023-02-27,Unknown
19301,EuroNext,Twitter API,Twitter,Euronext is cautious on acquiring Allfunds  a deal is anything butÂ certain https://t.co/qVgq23PSZD,nan,Euronext is cautious on acquiring Allfunds  a deal is anything butÂ certain https://t.co/qVgq23PSZD,neutral,0.16,0.83,0.01,neutral,0.16,0.83,0.01,True,English,"['Euronext', 'Allfunds', 'deal', 'qVgq23PSZD', 'Euronext', 'Allfunds', 'deal', 'qVgq23PSZD']",2023-02-27,2023-02-27,Unknown
19302,EuroNext,Twitter API,Twitter,.@euronext has confirmed it is in talks to buy wealth technology platform @allfunds_sau #FinancialAdvisersâ€¦ https://t.co/9zGQwVGTTi,nan,.@euronext has confirmed it is in talks to buy wealth technology platform @allfunds_sau #FinancialAdvisersâ€¦ https://t.co/9zGQwVGTTi,neutral,0.17,0.81,0.01,neutral,0.17,0.81,0.01,True,English,"['wealth technology platform', 'euronext', 'talks', 'FinancialAdvisers', 'wealth technology platform', 'euronext', 'talks', 'FinancialAdvisers']",2023-02-27,2023-02-27,Unknown
19303,EuroNext,Twitter API,Twitter,Euronext cautious on Allfunds acquisition  deal by no means certain https://t.co/DxoMMzDVF0,nan,Euronext cautious on Allfunds acquisition  deal by no means certain https://t.co/DxoMMzDVF0,neutral,0.12,0.81,0.07,neutral,0.12,0.81,0.07,True,English,"['Allfunds acquisition', 'Euronext', 'means', 'DxoMMzDVF0', 'Allfunds acquisition', 'Euronext', 'means', 'DxoMMzDVF0']",2023-02-27,2023-02-27,Unknown
19304,EuroNext,Twitter API,Twitter,. @euronext cautious on @Allfunds acquisition  deal by no means certain#markets #trading #manda #dealsâ€¦ https://t.co/g1nAgAHukH,nan,. @euronext cautious on @Allfunds acquisition  deal by no means certain#markets #trading #manda #dealsâ€¦ https://t.co/g1nAgAHukH,neutral,0.1,0.85,0.05,neutral,0.1,0.85,0.05,True,English,"['Allfunds acquisition', 'means', 'markets', 'manda', 'deals', 'Allfunds acquisition', 'means', 'markets', 'manda', 'deals']",2023-02-27,2023-02-27,Unknown
19305,EuroNext,Twitter API,Twitter,This Week in European Tech: Slava Ukraini  Volocopter tops up Series E round  Euronext chases â‚¬5.5 billion Allfundsâ€¦ https://t.co/oSg7vhqNrO,nan,This Week in European Tech: Slava Ukraini  Volocopter tops up Series E round  Euronext chases â‚¬5.5 billion Allfundsâ€¦ https://t.co/oSg7vhqNrO,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['Series E round', 'European Tech', 'Slava Ukraini', 'Volocopter', 'Euronext', 'Series E round', 'European Tech', 'Slava Ukraini', 'Volocopter', 'Euronext']",2023-02-27,2023-02-27,Unknown
19306,EuroNext,Twitter API,Twitter,If you missed the Euronext &amp; GUBERNA New Years event  you can now relive the atmosphere and engaging insights trougâ€¦ https://t.co/L2PsZ1DVU1,nan,If you missed the Euronext &amp; GUBERNA New Years event  you can now relive the atmosphere and engaging insights trougâ€¦ https://t.co/L2PsZ1DVU1,positive,0.71,0.23,0.06,positive,0.71,0.23,0.06,True,English,"['GUBERNA New Years event', 'engaging insights', 'Euronext', 'atmosphere', 'L2PsZ1DVU1', 'GUBERNA New Years event', 'engaging insights', 'Euronext', 'atmosphere', 'L2PsZ1DVU1']",2023-02-27,2023-02-27,Unknown
